Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
05 May 2009 - 9:20PM
PR Newswire (US)
JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals,
Inc. (OTC:ORMP) (http://www.oramed.com/), a developer of oral
delivery systems, announced that Phase 2b clinical trials will
commence this week on 30 Type 2 Diabetic volunteers. The study is
intended to evaluate the safety, tolerability and efficacy of its
oral insulin capsule ORMD-0801. OnQ Consulting, a clinical research
organization (CRO) located in Johannesburg, South Africa, will
oversee the clinical trials. This trial is an important milestone
for Oramed as it will test its first indication for ORMD-0801 on a
large group of volunteers for the duration of six weeks. This six
week randomized, double blind placebo controlled study will be
performed in three locations in Cape Town. The principle
investigators of the study will be renowned South African
Endocrinologists. "We are pleased to begin this study of ORMD-0801
on Type 2 diabetes patients following our successful 2A clinical
trials in August 2008. This trial is an important milestone for
Oramed as this is the first trial for ORMD-0801 on a larger group
of volunteers for a longer duration." said Oramed's CEO, Mr. Nadav
Kidron. About Oramed Pharmaceuticals Oramed Pharmaceuticals is a
technology pioneer in the field of oral delivery solutions for
drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule
currently in phase 2 clinical trials. Established in 2006, Oramed's
technology is based on over 25 years of research by top research
scientists at Jerusalem's Hadassah Medical Center. The Company's
corporate and R&D headquarters are based in Jerusalem. For more
information, please visit http://www.oramed.com/ Forward-looking
statements Some of the statements contained in this press release
are forward-looking statements which involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry
results, to be materially different from any future results,
performance or achievements expressed or implied by such forward
looking statements, including the risks and uncertainties related
to the progress, timing, cost, and results of clinical trials and
product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements. Company and Investor
Relation Contacts: Oramed Pharmaceuticals Tara Horn Cell:
+972-54-334-318 Office: +972-2-566-0001 Email: DATASOURCE: Oramed
Pharmaceuticals Inc. CONTACT: Company and Investor Relation
Contacts: Oramed Pharmaceuticals, Tara Horn, Cell: +972-54-334-318,
Office: +972-2-566-0001, Email:
Copyright